How CRISPR Works

Bacteria have an immune system. It’s nothing like ours, with no cells, antibodies, or fever. Instead, bacteria remember past viral attackers by storing snippets of their DNA in their own genome. When the same virus appears again, the bacteria use those snippets to recognize and destroy it. Scientists discovered this system, borrowed it, and turned it into the most powerful genetic engineering tool ever created.

The short answer

CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a gene-editing technology that allows scientists to make precise changes to DNA. It works by using a protein called Cas9 paired with a short RNA sequence called a guide RNA.

The guide RNA acts like a GPS: it carries a sequence of genetic code that matches the DNA location you want to target. Cas9 is the scissors: it cuts the DNA at that exact location. Once the DNA is cut, the cell’s natural repair mechanisms kick in, and scientists can use this opportunity to disable a gene, correct a mutation, or insert new genetic material.

The full picture

The bacterial immune system it came from

The CRISPR system was discovered in bacteria long before anyone imagined using it as a tool. In the 1980s and 90s, researchers — including Francisco Mojica at the University of Alicante, who first characterized the repeating sequences — noticed a strange pattern in bacterial DNA: repeated sequences interspersed with unique sequences. The unique sequences turned out to be fragments of DNA from viruses that had attacked the bacteria in the past.

When a virus infects a bacterium and the bacterium survives, it stores a piece of the virus’s DNA in this archive. On the next infection, the bacterium makes a copy of that stored snippet as an RNA molecule (the guide RNA). This RNA seeks out matching sequences in the virus’s DNA. When it finds a match, a protein called Cas9 cuts the viral DNA, neutralizing the threat.

Two scientists, Jennifer Doudna (University of California, Berkeley) and Emmanuelle Charpentier (Max Planck Unit for the Science of Pathogens), figured out in 2012 that you could reprogram this system. By changing the sequence of the guide RNA, you could direct Cas9 to cut any DNA sequence you chose, not just viral DNA. They shared the Nobel Prize in Chemistry in 2020 for this insight, becoming the first all-female pair to win a Nobel Prize jointly.

The mechanics of a CRISPR edit

The process begins with designing the guide RNA. If you want to edit a specific gene, you find the DNA sequence of that gene and synthesize a guide RNA that matches a 20-letter stretch of it (DNA uses a four-letter alphabet: A, T, C, G, so “20 letters” means 20 nucleotide bases).

The guide RNA and the Cas9 protein are assembled together and delivered into the target cell. Once inside, the guide RNA scans the cell’s DNA, unzipping the double helix as it goes, checking sequences until it finds a match. When it binds to the matching sequence, Cas9 cuts both strands of the DNA.

Now the cell faces a broken chromosome. It panics and tries to repair it. Two repair pathways kick in:

NHEJ (Non-Homologous End Joining) is fast and sloppy: it glues the cut ends back together, often with small insertions or deletions that disrupt the gene’s function. This is useful for disabling genes.

HDR (Homology-Directed Repair) is precise but slow: if you provide a DNA template alongside the Cas9 complex, the cell can use it as a blueprint to repair the cut with the new sequence. This is how you correct a mutation or insert new genetic material.

Delivery: getting CRISPR into cells

One of the main engineering challenges is getting the CRISPR machinery into the right cells in the first place. Several methods are used:

Viral vectors: Scientists borrow a virus’s natural ability to infect cells and insert genetic material. The virus is modified to be harmless but retains its delivery mechanism. This works well for reaching many cells in the body.

Lipid nanoparticles: Tiny fat-based particles can be loaded with CRISPR components and injected into the bloodstream. The first approved CRISPR therapy for sickle cell disease, Casgevy (developed by Vertex Pharmaceuticals and CRISPR Therapeutics), uses this approach to reach stem cells in bone marrow.

Electroporation: Cells are exposed to electric pulses that temporarily make their membranes permeable, allowing CRISPR components to enter. This works well for cells edited in the lab.

Off-target effects: the precision problem

CRISPR’s guide RNA can sometimes bind to sequences that are similar but not identical to the target, and Cas9 might cut at those unintended locations. These off-target edits are one of the main safety concerns.

Researchers have developed improved variants of Cas9 that are more precise, plus new tools that can check a cell’s entire genome after editing to map every cut that was made. The technology has improved dramatically since 2012.

A related tool called base editing can change a single DNA letter without cutting the double helix at all, reducing the risk of off-target cuts. Another called prime editing uses a modified Cas9 that can search, copy, and paste new DNA sequences, offering even more flexibility.

What CRISPR has already done

In December 2023, the FDA and UK Medicines and Healthcare products Regulatory Agency (MHRA) granted the first-ever regulatory approvals for a CRISPR-based therapy: Casgevy, developed by Vertex Pharmaceuticals and CRISPR Therapeutics, for the treatment of sickle cell disease and beta-thalassemia. These are inherited blood disorders caused by mutations in hemoglobin genes. Patients’ own stem cells are removed, edited to restore normal hemoglobin production, and returned to their body.

Clinical trials are underway for a range of conditions: hereditary blindness, certain cancers, HIV, and high cholesterol caused by a single faulty gene.

Base editing and prime editing: CRISPR’s more precise successors

Standard CRISPR-Cas9 cuts DNA, relies on the cell’s own repair machinery to make changes, and those repairs aren’t always clean. The cell might insert or delete a few random nucleotides, often enough to disable a gene, but not reliable enough for precise substitutions. This is useful for some applications, but medical treatments often need to change a specific letter in the genetic code, not just disrupt a gene.

Base editing, developed around 2016 by David Liu’s lab at the Broad Institute of MIT and Harvard, avoids cutting the DNA double helix entirely. Instead, it chemically converts one DNA base directly to another, changing C to T, or A to G, with a modified Cas9 that’s been fused to an enzyme capable of making that conversion. It’s closer to using a pencil with an eraser than a pair of scissors: you correct a specific letter rather than cutting and hoping the cell repairs it correctly.

Prime editing (2019) goes further still. Also developed by David Liu’s lab at the Broad Institute, it uses a modified Cas9 fused to a reverse transcriptase enzyme, guided by an RNA template that specifies exactly what change to make. It can insert, delete, or substitute any combination of nucleotides without making a double-strand break. Researchers call it a “search and replace” for DNA. Liu won the 2025 Breakthrough Prize in Life Sciences for these contributions.

These advances matter because the vast majority of known disease-causing mutations are point mutations, single-letter changes in the genetic code. Sickle cell disease is caused by a single A-to-T mutation. Most hereditary forms of early-onset Alzheimer’s come from specific single-letter changes. Base editing and prime editing can, in principle, correct these directly. We are moving from a technology that cuts genes toward one that rewrites them word by word.

Common misconceptions

CRISPR can edit any gene with perfect accuracy. Off-target effects occur where the guide RNA binds to similar but incorrect DNA sequences. Researchers are improving precision, but it’s not flawless.

CRISPR is only used for editing human genes. Most current applications are in research (understanding gene function), agriculture (crops with improved traits), and now approved human therapies. Human genome editing is still rare and highly regulated.

Gene editing is the same as gene therapy. Gene therapy typically adds a functional gene to compensate for a broken one. Gene editing modifies the existing DNA sequence, either correcting a mutation or disrupting a harmful gene.

CRISPR was invented by scientists in a lab. The system was discovered in bacteria as a natural immune mechanism. Scientists repurposed it as a tool.

Why it matters

Before CRISPR, editing a specific gene required slow, expensive, imprecise methods that took years of work. CRISPR made gene editing fast (weeks), cheap (thousands of dollars versus millions), and widely accessible. It democratized a technology that had previously been confined to a handful of specialized labs.

The implications span medicine, agriculture, and basic science. For medicine: treating genetic diseases at their root cause. For agriculture: crops that resist drought or disease. For science: any gene can now be turned off to understand its function, accelerating biological research across every field.

CRISPR also raises serious ethical questions, especially around germline editing: changes to embryos that would be inherited by all future descendants. In 2018, Chinese scientist He Jiankui claimed to have edited human embryos to confer HIV resistance — a use condemned by the global scientific community as premature and ethically unjustified. The scientific community, including bodies like the International Commission on the Clinical Use of Human Germline Genome Editing (convened by the US National Academies, the Royal Society, and others), is actively debating where the lines should be drawn. The technology is ready before society has finished deciding how to use it.